"ELI LILLY HAS CLAIMED THAT JOHNSON’S TRAGIC DEATH WAS AN ISOLATED INCIDENT Eli Lilly has claimed that Johnson’s tragic death was an isolated incident. Still, the FDA ordered Eli Lilly to stop accepting new volunteers for the study and to have continuing participants evaluated by an independent psychiatrist and sign new consent forms.

But in another Cymbalta trial of 4,124 depressed patients just weeks later, four more participants committed suicide. In 2005, Eli Lilly stopped seeking approval for Yentreve in the US. The company did not say why the drug was not approved, nor was it required to do so by the FDA.

The publicity surrounding the Johnson suicide raised concerns among researchers and physicians about Cymbalta’s safety. Some went to the FDA looking for answers, but the agency was silent.

The FDA said that the data from the clinical trials in question represented a “trade secret” that could not be released as Yentreve was never approved. This might be a perfectly acceptable reason for drug not on the market, but Eli Lilly was conducting these clinical trials to gain approval for new uses of Duloxetine.

Meanwhile, millions of people were already taking it as Cymbalta, and had no idea it had been associated with these suicides. Unfortunately, the FDA didn’t seem concerned that it might be protecting so-called trade secrets at the expense of patient safety."

https://www.yourlawyer.com/defective-drugs/cymbalta/cymbalta-suicide-data/?fbclid=IwAR1KTlrdJyxZKT2d_V-rO4RqlcDWefWSw7YVVaS-a5h-VVdzNQelrglCTGs